Linked Life Data

16806101

Source:http://linkedlifedata.com/resource/pubmed/id/16806101

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-1-15
pubmed:abstractText
Despite being approved for treating bipolar disorder, carbamazepine's (CBZ) mechanism of action is not fully understood. Carbamazepine and lithium, when administered chronically to rats, decrease brain messenger ribonucleic acid (mRNA), protein, and activity levels of the arachidonic acid-selective cytosolic phospholipase A2 (cPLA2). The ability of lithium to decrease cPLA2 mRNA was ascribed to its ability to down-regulate the cPLA2 transcription factor, AP-2. The present study was undertaken to see whether chronic CBZ treatment also would down-regulate the AP-2 transcription factor.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0006-3223
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
154-61
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Chronic administration of carbamazepine down-regulates AP-2 DNA-binding activity and AP-2alpha protein expression in rat frontal cortex.
pubmed:affiliation
Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. jrao@mail.nih.gov
pubmed:publicationType
Journal Article, Research Support, N.I.H., Intramural